Please assess the completion status of the following clinical trial:

Trial Title: Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects will be eligible for participation in this study if they:~  * Are ≥18 years on the day of screening~ * Had undergone an allogeneic HSCT 11 to 13 months ago (study population)~ * Are clinical healthy without previous TBE vaccination (control group)~ * Have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry~ * If female and capable of bearing children - have a negative urine pregnancy test result at study entry and agree to employ adequate birth control measures for the duration of the study~Exclusion Criteria:~* Subjects will be excluded from participation in this study if they:~  * Have received a TBE vaccination following HSCT~ * Suffer from extremely severe acute graft-versus host disease and therefore receive prednisone \>0.5 mg/kg bodyweight as part of a combination therapy or a three agent immunosuppressive treatment (because in these HSCT patients any type of vaccination has to be postponed until immunosuppression is reduced to a double combination or prednisone \<0.5 mg/kg bodyweight)~ * Suffer from or have a history of previous TBE virus infection or vaccination, previous dengue virus infection or vaccination against yellow fever or Japanese encephalitis~ * Have any acute febrile illness in the 2 weeks prior to or at the time of enrolment~ * Have a history of severe allergic reactions or anaphylaxis after vaccination~ * If female, are pregnant or lactating.~ * If belonging to the healthy control group, are immunosuppressed (suffer from or have a history of immune mediated diseases, long-term use of corticosteroids, hemodialysis, chronic renal insufficiency, liver cirrhosis Child-Pugh class C, hematooncological malignant disease, solid organ transplant, HSCT)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HSCT patients / TBE virus vaccine (Type: ACTIVE_COMPARATOR): Study population: patients who had undergone an allogeneic HSCT 11 to 13 months ago Eligible patients will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME-IMMUN®. Whenever possible, the patients will receive complete primary vaccination with a third dose of TBE vaccine (study visit 9 - 9 to 12 months after the first vaccination).
- healthy volunteers / TBE virus vaccine (Type: ACTIVE_COMPARATOR): Clinical healthy volunteers will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME IMMUN®. Whenever possible, the volunteers will receive complete primary vaccination with a third dose of TBE vaccine FSME IMMUN® (study visit 9 - 12 months after the first vaccination).

Based on this trial design, predict the completion outcome and termination type (if applicable).